To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge

NCT00881673 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Management decision

Conditions

Allergic Conjunctivitis

Interventions

DRUG: AL38583 Ophthalmic Solution
DRUG: Maxidex
DRUG: Vehicle

Sponsor

Alcon Research